Abstract
Introduction
Long-standing inflammation of the colorectum in ulcerative colitis (UC) and Crohn’s disease (CD) has been associated with an increased risk of subsequent dysplasia and colorectal cancer. Historically, it was described that the neoplastic transformation in these inflammatory bowel diseases (IBDs) occurred via a different biologic pathway and not by the non-IBD polyp-cancer pathway and predictable lag time of progression. Therefore, prevention strategies have focused on the detection of dysplasia in flat mucosa, and existing guidelines have recommended performance of interval surveillance colonoscopies with random biopsies to identify such lesions with proctocolectomy when they are confirmed.
Discussion
The use of a new technology higher-resolution colonoscopies has led to the appreciation more recently that dysplasia in IBD may be visible with standard optical colonoscopy and can be identified in an even more sensitive manner using chromoendoscopy. Furthermore, emerging evidence favors the intuitive understanding that neoplastic transformation in IBD is linked to the degree of inflammation and that disease control may therefore modify this risk and its subsequent prevention approaches.
Conclusion
Future IBD cancer prevention strategies and timing of surgery in at-risk patients will require a better understanding of this evolving field.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23(8):1097–1104. doi:10.1111/j.1365–2036.2006.02854.x.
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535. doi:10.1136/gut.48.4.526.
Rutter MD et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130(4):1030–1038. doi:10.1053/j.gastro.2005.12.035.
Jess T et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130(4):1039–1046. doi:10.1053/j.gastro.2005.12.037.
Rubin DT. The changing face of colorectal cancer in inflammatory bowel disease: progress at last!. Gastroenterology. 2006;130(4):1350–1352. doi:10.1053/j.gastro.2006.03.015.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371–1385. doi:10.1111/j.1572-0241.2004.40036.x.
Carter MJ et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1–16. doi:10.1136/gut.2004.043372.
Riddell RH, Goldman H, Ransohoff DF, Appelman HD et al. Dysplasia in Inflammatory Bowel Disease: Standardized Classification with Provisional Clinical Applications. Hum Pathol. 1983;14(11):931–968. doi:10.1016/S0046-8177(83)80175-0.
Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343(8889):71–74. doi:10.1016/S0140-6736(94)90813-3.
Ullman T et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125(5):1311–1319. doi:10.1016/j.gastro.2003.08.023.
Rubin DT, Kavitt RT. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35(3):581–604. doi:10.1016/j.gtc.2006.07.001.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997;92(2):204–211.
Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126(6):1634–1648. doi:10.1053/j.gastro.2004.03.025.
Rubin DT et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65(7):998–1004. doi:10.1016/j.gie.2006.09.025.
Rutter MD et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60(3):334–339. doi:10.1016/S0016-5107(04)01710-9.
Kiesslich R, Neurath MF. Chromoendoscopy and other novel imaging techniques. Gastroenterol Clin North Am. 2006;35(3):605–619. doi:10.1016/j.gtc.2006.07.004.
Kiesslich R et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124(4):880–888. doi:10.1053/gast.2003.50146.
Hurlstone DP et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy. 2005;37(12):1186–1192. doi:10.1055/s-2005-921032.
Kiesslich R et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007 Mar;132(3):874–882.
Dekker E et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007;39(3):216–221. doi:10.1055/s-2007-966214.
Bernstein CN. ALMs versus DALMs in ulcerative colitis: polypectomy or colectomy? Gastroenterology. 1999;117(6):1488–1492 editorial. doi:10.1016/S0016-5085(99)70300-8.
Blackstone MORR, Rogers BHG, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981;80:366–374.
Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117(6):1288–1294. discussion 1488–91. doi:10.1016/S0016-5085(99)70278-7.
Friedman S et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology. 2001;120(4):820–826. doi:10.1053/gast.2001.22449.
Nilubol N et al. Mucosal dysplasia in ileal pelvic pouches after restorative proctocolectomy. Dis Colon Rectum. 2007;50(6):825–831. doi:10.1007/s10350-007-0217-6.
Conflicts of interest
I have received consulting fees and grant support from Procter and Gamble Pharmaceuticals and Salix Pharmaceuticals.
I have received consulting fees from Axcan Pharma and Shire USA.
Author information
Authors and Affiliations
Corresponding author
Additional information
This paper was originally presented as part of the SSAT/AGA/ASGE State-of-the-Art Conference on Optimal Timing of Surgery for IBD at the SSAT 49th Annual Meeting, May 2008, in San Diego, CA. The other articles presented in the conference were Hodin RA, Introduction: Optimal Timing of Surgery for Inflammatory Bowel Diseases; McLeod RS, Ileal Pouch Anal Anastomosis: Pregnancy—Before, During and After; Sands BE, Fulminant Colitis; and Fleshman JW, Pyogenic Complications of Crohn’s Disease, Evaluation and Management.
Rights and permissions
About this article
Cite this article
Rubin, D.T. An Updated Approach to Dysplasia in IBD. J Gastrointest Surg 12, 2153–2156 (2008). https://doi.org/10.1007/s11605-008-0672-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-008-0672-y